Non-Small Cell Lung Cancer

In this study, the 42-patient population was enrolled from 5 sites in Canada and 1 site in Scotland, and data were gathered from March 7, 2019, to January 12, 2022; all had interstitial lung disease (ILD) and early-stage non–small cell lung cancer (NSCLC).

The approval converts the May 2021 accelerated FDA approval for second-line treatment of non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations to a full approval in the first line following results from the phase 3 PAPILLON study.

Investigators were searching for answers to the question, “Does it matter if a vein- or artery-first approach is used when performing a robotic lobectomy for non-small cell lung cancer (NSCLC)?

This most recent analysis from the CheckMate 9LA trial provides 4-year follow-up data on patients with stage IV metastatic/recurrent non–small cell lung cancer (NSCLC) randomized to treatment with nivolumab plus ipilimumab and chemotherapy vs chemotherapy alone.

The application is based on results of the phase 3 TROPION-Lung01 trial of datopotamab deruxtecan in nonsquamous non–small cell lung cancer (NSCLC), first presented at the 2023 European Society for Medical Oncology Congress.

Besides the new approval, AstraZeneca released preliminary results for LAURA evaluating osimertinib after chemoradiotherapy.

Coverage of Tennessee Oncology's Johann Brandes, MD, on "Precision Medicine in NSCLC."

Consolidation durvalumab led to comparable outcomes among older patients with unresectable stage III non–small cell lung cancer (NSCLC) vs a younger cohort with the same cancer; this patient population was underrepresented in the PACIFIC trial.

This retrospective analysis compared molecular testing outcomes among newly diagnosed cases of metastatic non–small cell lung cancer (mNSCLC) from 2 periods: March 2017 to May 2019 and July 2019 to March 2021.

Mark A. Socinski, MD, executive director at AdventHealth Cancer Institute, discusses the importance of lung cancer screening in eligible patients, including the need for primary care providers to ensure screening is being implemented.

Outcomes were evaluated among veterans treated for non–small cell lung cancer (NSCLC) from 2017 to 2020 with durvalumab, a PD-L1 inhibitor.

Melinda Aldrich, PhD, MHE, associate professor in the Vanderbilt University School of Medicine in the division of genetic medicine, discussed her ongoing research aiming to identify the drivers of disparities in lung cancer outcomes in the US.

The TROP-2–directed antibody drug conjugate is currently being investigated as a monotherapy and a combination therapy for non–small cell lung cancer (NSCLC) in 3 trials: phase 3 EVOKE-01, phase 2 EVOKE-02, and phase 3 EVOKE-03.

Molly Mendenhall, BSN, RN, director of quality and compliance at Oncology Hematology Care, Inc (OHC), discussed a 1-year quality improvement project implemented by OHC to standardize comprehensive biomarker testing in patients with non–small cell lung cancer (NSCLC).

This new study examined postoperative survival among discharged patients following treatment of non–small cell lung cancer (NSCLC) via surgical resection using the National Cancer Database.

Michael Gieske, MD, director of lung cancer screening at St. Elizabeth Health Care, speaks to the success of the Rural Appalachian Lung Cancer Screening Initiative, along with challenges to implementing increased lung cancer screening.

An early-phase, dose-escalation study of a hypofractionated approach to concurrent chemoradiation using an an adaptive stereotactic ablative radiotherapy (SABR) boost showed promising results in patients with locally advanced, unresectable non­­–small cell lung cancer (NSCLC).

Melinda C. Aldrich, PhD, MPH, associate professor in the departments of medicine, thoracic surgery, and biomedical informatics at Vanderbilt University, discussed recently updated lung screening guidelines from the American Cancer Society and the importance of equity across populations as new guidelines are developed.

Patients with non–small cell lung cancer (NSCLC) who tested positive for driver gene alteration had longer overall survival when given targeted therapy.

The addition of serplulimab to carboplatin and nab-paclitaxel significantly prolonged survival vs chemotherapy alone when used in the first-line treatment of patients with previously untreated locally advanced or metastatic squamous non–small cell lung cancer.

For patients with advanced non–small cell lung cancer (NSCLC), regardless of PD-L1 status, cemiplimab plus chemotherapy had favorable survival benefits and patient-reported outcomes over chemotherapy alone.

Repotrectinib achieved a high objective response rate and durable response in the pivotal TRIDENT-1 trial.

Pembrolizumab plus chemotherapy prior to surgery, followed by resection and single-agent pembrolizumab in the adjuvant setting, significantly improved overall survival (OS) vs neoadjuvant placebo plus chemotherapy followed by adjuvant placebo in patients with resectable stage II, IIIA, or IIIB (T3-4N2) non–small cell lung cancer, meeting the dual primary end point of the phase 3 KEYNOTE-671 trial.